Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection

FA (Floris) de Jong; RHJ Mathijssen; Peter de Bruijn; Walter Loos; Jaap Verweij; A Sparreboom

doi:10.1016/s1570-0232(03)00574-9

Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection

FA (Floris) de Jong
, RHJ Mathijssen
, Peter de Bruijn
, Walter Loos
, Jaap Verweij
, A Sparreboom^*

^*Corresponding author for this work

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

41 Citations (Scopus)

Abstract

An analytical method was developed for the anticancer agent irinotecan (CPT-11) and its main metabolite SN-38 in human whole blood and in red blood cells (RBCs). Sample pretreatment involved deproteinization of whole blood or plasma-diluted RBCs isolated by MESED instruments, with a mixture of aqueous perchloric acid and methanol (1:1, v/v). Separation was carried out using isocratic elution on a Hypersil ODS stationary phase, with detection at excitation and emission wavelengths of 355 and 515 nm, respectively. The lower limit of quantitation (LLQ) in blood was established at 5.00 ng/ml for both compounds, with values for within-run precision (WRP) and between-run precision (BRP) of less than 10%. The method is currently being applied to investigate the blood distribution of CPT-11 and SN-38 in cancer patients.

Original language	English
Pages (from-to)	383-388
Number of pages	6
Journal	Journal of Chromatography B-Biomedical Applications
Volume	795
Issue number	2
DOIs	https://doi.org/10.1016/s1570-0232(03)00574-9
Publication status	Published - 5 Oct 2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-03-86-08

Access to Document

10.1016/s1570-0232(03)00574-9

http://hdl.handle.net/1765/63015

Cite this

@article{6f7bf329d5434d2f8765a64805dc612c,

title = "Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection",

abstract = "An analytical method was developed for the anticancer agent irinotecan (CPT-11) and its main metabolite SN-38 in human whole blood and in red blood cells (RBCs). Sample pretreatment involved deproteinization of whole blood or plasma-diluted RBCs isolated by MESED instruments, with a mixture of aqueous perchloric acid and methanol (1:1, v/v). Separation was carried out using isocratic elution on a Hypersil ODS stationary phase, with detection at excitation and emission wavelengths of 355 and 515 nm, respectively. The lower limit of quantitation (LLQ) in blood was established at 5.00 ng/ml for both compounds, with values for within-run precision (WRP) and between-run precision (BRP) of less than 10\%. The method is currently being applied to investigate the blood distribution of CPT-11 and SN-38 in cancer patients.",

author = "\{de Jong\}, \{FA (Floris)\} and RHJ Mathijssen and \{de Bruijn\}, Peter and Walter Loos and Jaap Verweij and A Sparreboom",

year = "2003",

month = oct,

day = "5",

doi = "10.1016/s1570-0232(03)00574-9",

language = "English",

volume = "795",

pages = "383--388",

journal = "Journal of Chromatography B-Biomedical Applications",

issn = "0378-4347",

publisher = "Elsevier",

number = "2",

}

Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection. / de Jong, FA (Floris); Mathijssen, RHJ ; de Bruijn, Peter et al.
In: Journal of Chromatography B-Biomedical Applications, Vol. 795, No. 2, 05.10.2003, p. 383-388.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection

AU - de Jong, FA (Floris)

AU - Mathijssen, RHJ

AU - de Bruijn, Peter

AU - Loos, Walter

AU - Verweij, Jaap

AU - Sparreboom, A

PY - 2003/10/5

Y1 - 2003/10/5

N2 - An analytical method was developed for the anticancer agent irinotecan (CPT-11) and its main metabolite SN-38 in human whole blood and in red blood cells (RBCs). Sample pretreatment involved deproteinization of whole blood or plasma-diluted RBCs isolated by MESED instruments, with a mixture of aqueous perchloric acid and methanol (1:1, v/v). Separation was carried out using isocratic elution on a Hypersil ODS stationary phase, with detection at excitation and emission wavelengths of 355 and 515 nm, respectively. The lower limit of quantitation (LLQ) in blood was established at 5.00 ng/ml for both compounds, with values for within-run precision (WRP) and between-run precision (BRP) of less than 10%. The method is currently being applied to investigate the blood distribution of CPT-11 and SN-38 in cancer patients.

AB - An analytical method was developed for the anticancer agent irinotecan (CPT-11) and its main metabolite SN-38 in human whole blood and in red blood cells (RBCs). Sample pretreatment involved deproteinization of whole blood or plasma-diluted RBCs isolated by MESED instruments, with a mixture of aqueous perchloric acid and methanol (1:1, v/v). Separation was carried out using isocratic elution on a Hypersil ODS stationary phase, with detection at excitation and emission wavelengths of 355 and 515 nm, respectively. The lower limit of quantitation (LLQ) in blood was established at 5.00 ng/ml for both compounds, with values for within-run precision (WRP) and between-run precision (BRP) of less than 10%. The method is currently being applied to investigate the blood distribution of CPT-11 and SN-38 in cancer patients.

U2 - 10.1016/s1570-0232(03)00574-9

DO - 10.1016/s1570-0232(03)00574-9

M3 - Article

C2 - 14522044

SN - 0378-4347

VL - 795

SP - 383

EP - 388

JO - Journal of Chromatography B-Biomedical Applications

JF - Journal of Chromatography B-Biomedical Applications

IS - 2

ER -

Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection

Abstract

UN SDGs

Research programs

Access to Document

Fingerprint

Cite this